OM-89
Phase 3Small molecule
OM-89 is one of 5 small molecule programs targeting Chronic Prostatitis. It is currently in Phase 3.
1
Indications
2
Total Trials
2
Active Trials
4
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
5 competitors in Chronic Prostatitis
#DrugCompanyPhaseTrials
1OM-89
AAJU Pharm Co., Ltd.
Phase 3
Flomax
SanofiPreclinical
Levaquin
WWim Janssens
Preclinical
Detrol La
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Medication
NNYU Langone Health
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Chronic Prostatitis1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for OM-89. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- AAJU Pharm Co., Ltd.